MetALD is a recently coined term that refers to a systemic entity to describe patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and simultaneous moderate alcohol consumption. The deleterious association of alcohol and metabolic risk factors synergistically increases the development of steatohepatitis, fibrosis, and hepatocellular carcinoma (HCC). Despite its increasing incidence, the pathophysiological mechanisms triggering…
npj Gut and Liver Template
Write in a clean editor, then format for npj Gut and Liver in one click — DocuGuru applies the official Springer Nature template with superscript references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the npj Gut and Liver format
npj Gut and Liver is a peer-reviewed journal published by Springer Nature, covering Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Gastrointestinal motility and disorders. Over its lifetime it has published 67 papers, which have received 270 citations.
| Publisher | Springer Nature |
|---|---|
| Reference style | Superscript numbered (Nature) Superscript — small raised numerals in the text 1. Smith, A., Jones, B. & Lee, C. A representative article title. npj Gut and Liver 12, 45–58 (2023).
Formats any DOI in npj Gut and Liver style. No sign-up. |
| Publishes research in | Liver Disease Diagnosis and Treatment Liver Disease and Transplantation Gastrointestinal motility and disorders Diet and metabolism studies Diet, Metabolism, and Disease |
| ISSN | 3004-9806 |
| Citation impact (2-yr) | 4.03 |
| h-index | 8 |
| i10-index | 8 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | Mayo Clinic in Arizona |
| Journal website | {http://link.springer.com/journal/44355,https://www.nature.com/npjgutliver/} |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in npj Gut and Liver per year
Citation impact of npj Gut and Liver by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in npj Gut and Liver
Metabolic Dysfunction-Associated Steatohepatitis (MASH), the advanced stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is a leading cause of chronic liver disease, driving cirrhosis, liver cancer, and mortality. With metabolic, genetic, and environmental factors at play, early detection and treatment are critical. This review highlights the latest breakthroughs in MASH pathophysiology, cost-effective noninvasive diagnostics, and…
Developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) has been a surprisingly challenging task. To effectively treat MASH, the drug should address the three key issues associated with these conditions: fat accumulation, inflammation, and fibrosis. However, no therapeutic drugs have been able to meet all the required criteria, especially when it comes to improving fibrosis. With…
Blood ammonia levels in healthy individuals are low, but they increase in liver disease due to loss of functional liver mass and portosystemic shunting. Hyperammonemia is one of the key factors involved in the prognosis of cirrhosis and its complications. Here we review to establish a connection between alterations in gut microbial communities and intestinal…
Around 5.3% of adults worldwide are living with metabolic dysfunction-associated steatohepatitis (MASH). As liver fibrosis develops, their incidence of cirrhosis, hepatocellular carcinoma, cardiovascular complications, and non-liver cancer increases. We analyse MAESTRO-NASH resmetirom data and discuss real-world implications following approval. US-based patients now have a novel treatment and expert use recommendations. We anticipate that the UK…